Major Depressive Disorder In The Elderly

GlaxoSmithKline364 enrolled

Overview

This is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with Major Depressive Disorder (MDD).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

364

Conditions

Depressive Disorder, Major

Interventions

bupropion XLDRUG

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primary diagnosis of Major Depressive Disorder with DSM-IV criteria for their current episode for at least 8 weeks. Exclusion Criteria: * Patient has current or past history of seizure disorder or brain injury. * Patient has a diagnosis of anorexia or bulimia within the past 12 months. * Patient has a past or current DMS-IV diagnosis of schizophrenia or any other psychotic disorder(s). * Patient has had a myocardial infarction within 1 year or a history of uncontrolled hypertension or unstable heart disease with 6 months.

Locations (16)

GSK Investigational Site

Caboolture, Queensland, Australia

GSK Investigational Site

Everton Park, Queensland, Australia

GSK Investigational Site

New Farm, Queensland, Australia

Outcomes

Primary Outcomes

Montgomery-Asberg Depression Rating Scale

Secondary Outcomes

Montgomery-Asberg Depression Rating Scale Clinical Global Impression Improvement Scale Clinical Global Impression Severity Scale Hamilton Anxiety Rating Scale

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.